drugset / Trial / NCT02057445
3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma
Phase 1
Completed
1 enrolled
New York Medical College
Baylor College of Medicine · collabChildren's National Research Institute · collabCity of Hope Medical Center · collabJohns Hopkins University · collabM.D. Anderson Cancer Center · collabOhio University · collabUniversity of Michigan · collabUniversity of Utah · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The administration of allogeneic third party derived LMP specific-CTLs (special peripheral blood cells from another person) that are made specific to fight EBV infection) in Children, Adolescents and Young Adults (CAYA) with EBV-associated refractory or relapsed lymphoma will be feasible ( able to be done), safe and well tolerated (no unexpected serious events will occur). In addition, potential donors who are EBV positive will be enrolled to donate peripheral blood to help build a bank of these specific EBV fighting cell lines.
Timeline
- Start
- 2014-01
- Primary completion
- 2016-12
- Completion
- 2017-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | EBV CTL's | Cell therapy | — | Other |